A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer
- 18 April 2009
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 64 (6), 1181-1185
- https://doi.org/10.1007/s00280-009-0981-1
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancerBritish Journal of Cancer, 2001
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996